Maduck Sean 4
Research Summary
AI-generated summary
Corcept (CORT) President Sean Maduck Gifts 54,570 Shares
What Happened
- Sean Maduck, President of Corcept Endocrinology, reported intra-personal transfers on Jan 8, 2026 that are reported as gifts. He disposed of a total of 54,570 shares (20,570 and 34,000) at $0.00 per share (total reported value $0). Matching "other acquisition or disposition" (code J) entries for the same amounts were also reported, reflecting transfers into accounts/entities for which he serves in fiduciary or managerial roles.
- These were not sales for cash — they were gifts/transfers and therefore do not directly indicate a buy or sell investment decision.
Key Details
- Transaction date(s): January 8, 2026; Price: $0.00 per share; Total shares transferred: 54,570.
- Form filed: February 13, 2026 (period of report: 2026-01-08). The filing was submitted roughly 36 days after the transaction date and appears late relative to the typical 2-business-day Form 4 filing requirement.
- Shares owned after transaction: not specified in the excerpt provided — see the full Form 4 for total beneficial ownership.
- Relevant footnotes: transfers involve trusts and entities where Maduck is trustee, co-trustee, member or manager (F1–F6). F4 lists 1,587 unvested restricted shares (266 + 888 + 228 + 205) that vest one year after each grant date; F6 notes Duckhill Capital, LLC holdings for which he disclaims beneficial ownership except to the extent of pecuniary interest.
- Remark on role: Reporting person listed as President, Corcept Endocrinology. Power of attorney under which the form was signed is on file with the SEC.
Context
- Gift transactions (code G) are transfers of shares without cash consideration and generally do not signal the insider’s view on the company’s stock. Code J entries (other acquisition/disposition) are commonly used to report transfers between accounts or into trusts/LLCs rather than market trades.
- Because the transfers involve trusts and entities that Maduck manages or serves as trustee, these filings largely reflect reallocation of ownership/control, not open-market selling.